FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease – Bio Tech Winners
June 9, 2024 by Leave a Comment Last Updated on June 9, 2024 by [#item_full_content] Like this: Like Loading… Related Filed Under: biotech news, News Reader Interactions This site uses Akismet to reduce spam. Learn how your comment data is processed. Source link